Vertex Acquires Crinetics for $10 Billion; Viking Therapeutics Seen as Potential Next Target
In a major move, Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $10 billion in cash. This is the largest acquisition in Vertex's history and aims to bolster its endocrinology pipeline with promising drug candidates from Crinetics. The biopharmaceutical industry remains active in M&A as companies seek fast-track access to innovative therapies, particularly in high-growth areas like anti-obesity treatments. Viking Therapeutics (NASDAQ: VKTX) is emerging as a potential acquisition target due to its strong pipeline of weight-loss drugs, including phase 3 candidate VK2735 and early-stage asset VK3019. With the global obesity drug market projected to grow from $79 billion in 2024 to nearly $190 billion by 2035, pharmaceutical giants are increasingly looking for strategic acquisitions. Viking's progress with its GLP-1/GIP agonist therapies positions it as an attractive option for larger firms seeking rapid entry into this expanding sector.
Topics: Crinetics acquisition pharma M&A Vertex Pharmaceuticals Viking Therapeutics